50
Participants
Start Date
September 14, 2024
Primary Completion Date
March 18, 2025
Study Completion Date
May 16, 2025
Recombinant Botulinum Toxin Type A for injection (YY001)
Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort)/ 300 U (medium dose cohort)/ 400 U (high dose cohort).
BOTOX®
Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection, the total injection dose is 200 U (low dose cohort).
Placebo
Single treatment, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), intramuscular injection.
RECRUITING
Anhui Provincial Hospital, Hefei
RECRUITING
The Second People's Hospital of Hefei, Hefei
RECRUITING
Peking Union Medical College Hospital, Beijing
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
Sun Yat-sen Memorial Hospital, Guangzhou
RECRUITING
Shenzhen Second People's Hospital, Shenzhen
RECRUITING
The First Affiliated Hospital of Henan University, Kaifeng
RECRUITING
RenMin Hospital Of Wuhan University, Wuhan
RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
RECRUITING
Xuzhou Medical University Affiliated Hospital, Xuzhou
RECRUITING
Qilu Hospital of Shandong University, Qingdao
RECRUITING
Rui Jin Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai
RECRUITING
Shanghai Fudan University HuaShan Hospital, Shanghai
RECRUITING
Yangzhi Affiliated Rehabilitation Hospital of Tongji University, Shanghai
RECRUITING
Shanxi Bethune Hospital, Taiyuan
RECRUITING
Shanxi provincial people's Hospital, Taiyuan
RECRUITING
West China Hospital，Sichuan University, Chengdu
RECRUITING
Tianjin Medical University General Hospital, Tianjin
RECRUITING
The Second Affiliated Hospital of Kunming Medical University, Kunming
Chongqing Claruvis Pharmaceutical Co., Ltd.
INDUSTRY